Access Financial Services Inc. lifted its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 65.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,407 shares of the medical research company’s stock after buying an additional 954 shares during the quarter. Access Financial Services Inc.’s holdings in Amgen were worth $419,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently made changes to their positions in the company. FMR LLC grew its position in Amgen by 4.8% in the 2nd quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock valued at $9,817,037,000 after purchasing an additional 2,587,041 shares during the period. Vanguard Group Inc. grew its position in Amgen by 0.9% in the 2nd quarter. Vanguard Group Inc. now owns 52,146,935 shares of the medical research company’s stock valued at $8,981,266,000 after purchasing an additional 489,720 shares during the period. BlackRock Inc. grew its position in Amgen by 1.9% in the 2nd quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock valued at $8,516,980,000 after purchasing an additional 909,689 shares during the period. Bank of New York Mellon Corp grew its position in Amgen by 1.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 8,166,002 shares of the medical research company’s stock valued at $1,522,551,000 after purchasing an additional 140,117 shares during the period. Finally, Nordea Investment Management AB grew its position in Amgen by 12.9% in the 2nd quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock valued at $1,212,602,000 after purchasing an additional 806,119 shares during the period. 78.95% of the stock is owned by institutional investors.
In other news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $174.18, for a total transaction of $265,624.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 4,575 shares of company stock worth $818,361 over the last quarter. Company insiders own 0.19% of the company’s stock.
AMGN has been the topic of several recent analyst reports. Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $199.00 price objective on the stock in a research note on Friday, October 27th. Citigroup cut Amgen to a “neutral” rating in a research note on Monday, December 18th. Royal Bank of Canada dropped their price objective on Amgen from $192.00 to $188.00 and set a “sector perform” rating on the stock in a research note on Thursday, October 26th. Goldman Sachs Group cut Amgen from a “conviction-buy” rating to a “buy” rating in a research note on Friday, December 15th. Finally, Argus upgraded Amgen from a “hold” rating to a “buy” rating and raised their price objective for the company from $192.33 to $220.00 in a research note on Tuesday, January 23rd. Sixteen equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $191.84.
Shares of Amgen, Inc. (AMGN) opened at $183.55 on Monday. The company has a market capitalization of $133,240.00, a price-to-earnings ratio of 16.69, a PEG ratio of 2.26 and a beta of 1.42. Amgen, Inc. has a 52 week low of $152.16 and a 52 week high of $201.23. The company has a debt-to-equity ratio of 1.35, a quick ratio of 5.17 and a current ratio of 5.49.
Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing the Zacks’ consensus estimate of $3.03 by ($0.14). The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. The company’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.89 earnings per share. research analysts predict that Amgen, Inc. will post 13.21 earnings per share for the current fiscal year.
Amgen announced that its Board of Directors has initiated a share buyback plan on Wednesday, October 25th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its stock is undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be paid a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.88%. This is a boost from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date is Wednesday, February 14th. Amgen’s payout ratio is presently 48.00%.
ILLEGAL ACTIVITY WARNING: “Amgen, Inc. (AMGN) Stake Increased by Access Financial Services Inc.” was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.thelincolnianonline.com/2018/02/19/amgen-inc-amgn-stake-increased-by-access-financial-services-inc.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.